Adverse Effect Management and the Role of Immunotherapy in NMIBC

Experts on bladder cancer discusses strategies to minimize adverse effects and the role of immunotherapy in BCG-unresponsive NMIBC treatment paradigms.

EP: 1.Navigating BCG Shortages in NMIBC

EP: 2.The Evolving Treatment Landscape in BCG-Unresponsive NMIBC

EP: 3.Efficacy and Safety Data from SunRISe-1

EP: 4.Overview of the QUILT Trial in BCG-Unresponsive NMIBC

EP: 5.Quality of Life and Progression Considerations in BCG-Unresponsive NMIBC

Now Viewing

EP: 6.Adverse Effect Management and the Role of Immunotherapy in NMIBC

EP: 7.Selecting Optimal Treatment in BCG-Unresponsive NMIBC

EP: 8.Patient Monitoring Strategies in BCG-Unresponsive NMIBC

EP: 9.Promising Developments in NMIBC

EP: 10.Key Takeaways on the Evolving NMIBC Treatment Landscape

Related Videos

Related Content

Advertisement

July 10th 2025

Data supports combination intravesical chemotherapy for high-risk NMIBC

Hannah Clarke

“This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

July 8th 2025

Enrollment complete for phase 3 UTOPIA trial in LG-IR-NMIBC

Benjamin P. Saylor Hannah Clarke

Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks.

May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke

Take a look through all the regulatory milestones in urology from the first half of the 2025.

July 4th 2025

Top 10 Urology Times videos from the first half of 2025

Urology Times staff

Catch up on exclusive videos you may have missed from the first half of the year.

Related Content

Advertisement

July 10th 2025

Data supports combination intravesical chemotherapy for high-risk NMIBC

Hannah Clarke

“This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

July 8th 2025

Enrollment complete for phase 3 UTOPIA trial in LG-IR-NMIBC

Benjamin P. Saylor Hannah Clarke

Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks.

May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke

Take a look through all the regulatory milestones in urology from the first half of the 2025.

July 4th 2025

Top 10 Urology Times videos from the first half of 2025

Urology Times staff

Catch up on exclusive videos you may have missed from the first half of the year.